NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD

Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD explained in plain language.

Never miss a new study

Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD trials appear

Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Gene therapy shot aims to tame wet AMD in both eyes

Disease control Recruiting now

This study tests a gene therapy called Ixo-vec in the second eye of people with wet age-related macular degeneration (AMD) in both eyes. Fifteen adults aged 50 and older will receive a single injection in the second eye and be followed for about 5 years. The goal is to see if the…

Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD

Phase: PHASE2 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control

Last updated Jun 27, 2026 13:03 UTC

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD

Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD trials appear

Gene therapy shot aims to tame wet AMD in both eyes